
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is well-positioned with its proprietary technology utilizing the alpha-emitting isotope Lead-212 to provide powerful and targeted radiation therapy for cancer treatment. With a growing market for radiopharmaceuticals and a diverse pipeline of programs, including its newly unveiled CCK2R targeting PSV594, Perspective Therapeutics shows potential for future growth and success. Upcoming data catalysts and a robust cash runway further support a positive outlook for this innovative radiopharmaceutical company.
Bears say
Perspective Therapeutics is facing potential risks to its valuation and price target, as their treatment approach relies on biodistribution and patient screening, which has yet to be fully validated. Additionally, there is growing competition in the radiopharmaceutical market, and the company's ability to secure favorable reimbursement and adoption for their products may also pose a challenge. Valuation is currently estimated at 8 times projected sales for their product candidates, but this is discounted back 35% due to uncertainties in their approach and market competition.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares